Health Care & Life Sciences » Biotechnology | Abeona Therapeutics Inc.

Abeona Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
424.00
11,520.00
40,138.00
69,142.00
137,750.00
84,968
Total Accounts Receivable
74.00
35.00
115.00
124.00
107.00
81
Other Current Assets
77.00
-
315.00
155.00
2,735.00
3,802
Total Current Assets
575.00
11,555.00
40,568.00
69,421.00
140,592.00
88,851
Net Property, Plant & Equipment
6.00
4.00
350.00
721.00
1,374.00
9,443
Intangible Assets
-
4,991.00
39,075.00
40,850.00
36,443.00
75,508
Other Assets
32.00
32.00
62.00
66.00
357.00
37
Total Assets
613.00
16,582.00
80,055.00
111,058.00
178,766.00
174,399
ST Debt & Current Portion LT Debt
-
400.00
-
-
-
Accounts Payable
863.00
1,896.00
875.00
3,694.00
2,393.00
Other Current Liabilities
8,098.00
602.00
602.00
4,602.00
3,214.00
Total Current Liabilities
8,961.00
2,898.00
1,477.00
8,296.00
5,607.00
Provision for Risks & Charges
-
-
2,591.00
-
-
Other Liabilities
6,431.00
8,868.00
8,266.00
3,664.00
3,061.00
Total Liabilities
15,392.00
11,766.00
12,334.00
11,960.00
8,668.00
Common Equity (Total)
14,779.00
4,816.00
67,721.00
99,098.00
170,098.00
Total Shareholders' Equity
14,779.00
4,816.00
67,721.00
99,098.00
170,098.00
Total Equity
14,779.00
4,816.00
67,721.00
99,098.00
170,098.00
Liabilities & Shareholders' Equity
613.00
16,582.00
80,055.00
111,058.00
178,766.00

About Abeona Therapeutics

View Profile
Address
1330 Avenue of the Americas
New York New York 10019
United States
Employees -
Website http://www.abeonatherapeutics.com
Updated 07/08/2019
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Dallas, TX.